pcDNA-HDAC6.DC-FLAG Citations (10)
Originally described in: The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress.Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP Cell. 2003 Dec 12. 115(6):727-38. PubMed Journal
Articles Citing pcDNA-HDAC6.DC-FLAG
| Articles |
|---|
| Novel Interaction of Class IIb Histone Deacetylase 6 (HDAC6) with Class IIa HDAC9 Controls Gonadotropin Releasing Hormone (GnRH) Neuronal Cell Survival and Movement. Salian-Mehta S, Xu M, McKinsey TA, Tobet S, Wierman ME. J Biol Chem. 2015 May 29;290(22):14045-56. doi: 10.1074/jbc.M115.640482. Epub 2015 Apr 14. PubMed |
| Class I and IIa HDACs Mediate HIF-1alpha Stability Through PHD2-Dependent Mechanism, While HDAC6, a Class IIb Member, Promotes HIF-1alpha Transcriptional Activity in Nucleus Pulposus Cells of the Intervertebral Disc. Schoepflin ZR, Shapiro IM, Risbud MV. J Bone Miner Res. 2016 Jun;31(6):1287-99. doi: 10.1002/jbmr.2787. Epub 2016 Mar 15. PubMed |
| Inhibition of HDAC6 activity through interaction with RanBPM and its associated CTLH complex. Salemi LM, Maitland MER, Yefet ER, Schild-Poulter C. BMC Cancer. 2017 Jul 1;17(1):460. doi: 10.1186/s12885-017-3430-2. PubMed |
| ARID1A-mutated ovarian cancers depend on HDAC6 activity. Bitler BG, Wu S, Park PH, Hai Y, Aird KM, Wang Y, Zhai Y, Kossenkov AV, Vara-Ailor A, Rauscher FJ III, Zou W, Speicher DW, Huntsman DG, Conejo-Garcia JR, Cho KR, Christianson DW, Zhang R. Nat Cell Biol. 2017 Aug;19(8):962-973. doi: 10.1038/ncb3582. Epub 2017 Jul 24. PubMed |
| HDAC6 Restricts Influenza A Virus by Deacetylation of the RNA Polymerase PA Subunit. Chen H, Qian Y, Chen X, Ruan Z, Ye Y, Chen H, Babiuk LA, Jung YS, Dai J. J Virol. 2019 Feb 5;93(4). pii: JVI.01896-18. doi: 10.1128/JVI.01896-18. Print 2019 Feb 15. PubMed |
| Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine gamma-lyase protein degradation. Chi Z, Byeon HE, Seo E, Nguyen QT, Lee W, Jeong Y, Choi J, Pandey D, Berkowitz DE, Kim JH, Lee SY. Pharmacol Res. 2019 Aug;146:104281. doi: 10.1016/j.phrs.2019.104281. Epub 2019 May 21. PubMed |
| Honokiol ameliorates angiotensin II-induced hypertension and endothelial dysfunction by inhibiting HDAC6-mediated cystathionine gamma-lyase degradation. Chi Z, Le TPH, Lee SK, Guo E, Kim D, Lee S, Seo SY, Lee SY, Kim JH, Lee SY. J Cell Mol Med. 2020 Sep;24(18):10663-10676. doi: 10.1111/jcmm.15686. Epub 2020 Aug 4. PubMed |
HDAC6 mediates an aggresome-like mechanism for NLRP3 and pyrin inflammasome activation.
Magupalli VG, Negro R, Tian Y, Hauenstein AV, Di Caprio G, Skillern W, Deng Q, Orning P, Alam HB, Maliga Z, Sharif H, Hu JJ, Evavold CL, Kagan JC, Schmidt FI, Fitzgerald KA, Kirchhausen T, Li Y, Wu H.
Science. 2020 Sep 18;369(6510). pii: 369/6510/eaas8995. doi: 10.1126/science.aas8995.
PubMed
Associated Plasmids |
| Inhibition of HDAC6 Activity Protects Against Endothelial Dysfunction and Atherogenesis in vivo: A Role for HDAC6 Neddylation. Nomura Y, Nakano M, Woo Sung H, Han M, Pandey D. Front Physiol. 2021 Jun 17;12:675724. doi: 10.3389/fphys.2021.675724. eCollection 2021. PubMed |
| HDAC6 promotes aggressive development of liver cancer by improving egfr mRNA stability. Dai HY, Chang LS, Yang SF, Wang SN, Su SJ, Yeh YT. Neoplasia. 2023 Jan;35:100845. doi: 10.1016/j.neo.2022.100845. Epub 2022 Nov 2. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.